Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622259 | 0.94 | PARP1 (0.88) | PARP1PARP2 | |
| SCHEMBL631291 | 0.94 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL631601 | 0.93 | PARP1 (0.98) | PARP1PARP2 | |
| SCHEMBL630587 | 0.92 | PARP1 (0.96) | PARP1PARP2 | |
| SCHEMBL5072065 | 0.91 | PARP1 (0.83) | PARP1PARP2 | |
| SCHEMBL6777446 | 0.90 | PARP1 (0.82) | PARP1PARP2 | |
| SCHEMBL631261 | 0.90 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL630747 | 0.89 | PARP1 (0.98) | PARP1PARP2 | |
| SCHEMBL630402 | 0.88 | PARP1 (0.95) | PARP1PARP2 | |
| SCHEMBL631570 | 0.86 | PARP1 (1.00) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | claimed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.